Detailed paper information

Back to list

Paper title Preliminary Experience with a Novel Drug Coating Balloon Catheter for Symptomatic Intracranial High-grade Stenosis
Paper code P62
  1. Philipp Gruber Kantonsspital Aarau AG Speaker
  2. Timo Kahles Kantonsspital Aarau AG
  3. Jatta Berberat Kantonsspital Aarau
  4. Martin Hlavica
  5. Javier Anon Kantonsspital Aarau AG
  6. Michael Diepers Kantonsspital Aarau
  7. Krassen Nedeltchev Kantonsspital Aarau
  8. Luca Remonda Kantonsspital Aarau AG
Form of presentation Poster
  • SSNR-Neuroradiology
Abstract text Objective: Intracranial arteriosclerotic disease is a relevant cause of ischemic stroke worldwide. Despite best medical treatment, the re-occurrence rate is high. Because of the discouraging SAMMPRIS trial [1], neurovascular treatment remained as a second line therapy. Since, there has been tremendous advance in device technology. SeQuent Please NEO (B.Braun, Melsungen, Germany) is a novel polymer-free, drug coated (paclitaxel/iopromide) balloon (DCB) primarily designed for cardiology. Because of its high flexibility and pushability it seems to be suitable also for intracranial use. Furthermore, it offers a sustained anti-proliferative effect and natural vessel restoration. The aim of this case series was to assess feasibility and safety of Sequent Please NEO in symptomatic intracranial high-grade stenosis.
Method: A single-center case series of 12 patients with symptomatic intracranial high-grade stenosis between 09/2016–01/2018 treated with SeQeunt Please NEO DCB executed at a tertiary stroke center in Switzerland.
Results: 12 patients (100% men, median ages 73 years (interquartile range (IQR) 70-77) were treated with SeQuent Please NEO. Median pre-treatment carotid stenosis grade was 78% (IQR 75-80) with 2 mid-basilar, 5 internal cerebral artery and 5 vertebral artery lesions. Median post-treatment stenosis grade was 50% (IQR 45-52). Successful angioplasty was achieved in all cases without technical failure and no peri-procedural re-occlusion rates and no mortality rate at follow-up.
Conclusion: SeQuent Please NEO CDB demonstrates to be feasible and safe in symptomatic intracranial high-grade stenosis. Therefore, it might constitute a promissing alternative to medical treatment.